BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets
Summary
BioVaxys will also issue common stock valued at $250,000 to HIMV, an acquisition company formed of Horizon Technology and other secured creditors for IMV. IMV’s portfolio consists of a cancer vaccine, maveropepimut-S (MVP-S), developed using the DPX antigen delivery platform, which is also part of the acquisition. The open-label Phase II VITALIZE (NCT04920617) and AVALON (NCT05243524) trials evaluating MVP-S as a combination therapy with MSD’s Keytruda (pembrolizumab) in r/r DLBCL, and with chemotherapy in platinum-resistant ovarian cancer, respectively, paused enrolment in May 2023 as part of the bankruptcy proceedings. The transaction also includes an influenza vaccine, an investigational therapeutic for advanced metastatic bladder cancer, and DPX-Covid-19. BioVaxys had also tried to enter the medical software business and acquired clinical studies management company TAETSoftware in March 2023.